Heart Failure Drug Shows Beneficial Metabolic Effects in PARADIGM-HF Trial
MARCH 17, 2017
Sacubitril/valsartan (Entresto/Novartis) became the first angiotensin receptor neprilysin inhibitor for to be approved for chronic heart failure with reduced ejection fraction (HFrEF) by the US Food and Drug Administration (FDA) in July 2015. In the PARADIGM-HF trial, the drug combination was observed in patients with a history of type 2 diabetes and HFrEF.
Scott Solomon, MD, director of Noninvasive Cardiology at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, revealed the results of PARADIGM-HF to MD Magazine during an interview at the 66th Scientific Session of the American College of Cardiology (ACC 2017) in Washington, District of Columbia.
“We didn’t expect to see this,” Solomon said. “The trial was designed as a heart failure trial, but here we have a heart failure drug that also has very beneficial metabolic effects as well.”
This information becomes very important for doctors who treat patients with heart failure who also have diabetes, Solomon said.
>>> More Coverage from ACC 2017